PC
ARNA

PointState Capital’s Arena Pharmaceuticals Inc ARNA Stock Holding History

PointState Capital’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-447,400
Closed -$19.5M – 197
2018
Q2 		$19.5M Buy
447,400
+352,300
+370% +$15.1M 0.22% 79
2018
Q1 		$3.76M Buy
+95,100
New +$3.7M 0.04% 120

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

PointState Capital's ARNA Position: Q3 2018 in Review

PointState Capital sold out of Arena Pharmaceuticals Inc (ARNA) in Q3 2018, closing a stake of 447,400 shares — an estimated $19.5M sold.

PointState Capital first reported a position in ARNA in Q1 2018 and held it in 2 quarters. The position peaked at $19.5M in Q2 2018. 160 funds tracked by Wall St. Rank hold ARNA as of Q3 2018.

  • PointState Capital reported no remaining Arena Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • PointState Capital sold 447,400 Arena Pharmaceuticals Inc shares in Q3 2018, an estimated $19.5M.
  • PointState Capital first reported a position in Arena Pharmaceuticals Inc in Q1 2018 and held it in 2 quarters.
  • PointState Capital's Arena Pharmaceuticals Inc position peaked at $19.5M in Q2 2018.
  • 160 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q3 2018.

Based on PointState Capital's 13F filing for Q3 2018, filed 14 Nov 2018.